Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Mini-Berkshire Hathaway Acquiring a Competitor: Markel Corporation (MKL)

Breakdown of the deal

The deal doubles the size of Markel.  It will give Markel equal parts short and long insurance premiums with two thirds from insurance and one third reinsurance.  The merger increases exposure to catastrophe risk at Markel.  There are cost savings and diversification benefits for Markel.  In addition, management plans to allocate Alterra’s investment portfolio in a similar manner to Markel’s.  The idea here is that Markel is a better investment manager and with the merger, has more assets to manage.  Management believes this will create value for shareholders.

Get long Markel?

Markel shares have performed in line with the S&P 500 over the past five years.  Late in 2012, the stock started to break out and finally outperform the index.  Since the deal, the shares have retreated on concerns noted earlier.  The bull case argues the shares can have a superior growth profile and value may come from Markel’s opportunity to cross-sell their products to Alterra customers and vice versa.  Additionally, Markel will have a new customer base it can sell to and adds underwriting capabilities where the company can offer larger limits without increasing use of reinsurance.  This may allow Markel to grow book value, earnings and ROE at a more rapid pace than as a standalone firm.

The article Mini-Berkshire Hathaway Acquiring a Competitor originally appeared on Fool.com and is written by Mike Thiessen.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!